• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Phathom

Quote
Phathom needs phast incoming cash phlow.

Phathom pheels a phenomenally pherocious sales phorce and phormulary wins will phoment a phantastic launch to phlame p.p.i.s and phavor phuture phrenetic prescribing of Voquezna.

We are Phathom Pharma Phamily.
We got Voquezna to stop gastric acidity!
 




anonymous said:
Phathom needs phast incoming cash phlow.

Phathom pheels a phenomenally pherocious sales phorce and phormulary wins will phoment a phantastic launch to phlame p.p.i.s and phavor phuture phrenetic prescribing of Voquezna.

We are Phathom Pharma Phamily.
We got Voquezna to stop gastric acidity!
Click to expand...



Voquezna? I hope the efficacy is better than the name.
 












Management is HORRIBLE! Rebecca has never been a manager. And they just hired a manager in the NY AREA named khandice O'Kelly. STAY AWAY. she was involved in a lawsuit when she was a manager at Amarin for targeting people. WORST HUMAN YOU WILL ever meet.
 




































I just accepted. Will give range so not identifiable.

$125-$140 base

hoping to cash in on the coming buyout. no way they can make payroll over the long term without someone buying them.

I'll keep interviewing all the same.

Phocused on the Phuture.
 




























Top Bottom
Back
Quote